Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SD BioSensor, Inc (137310.KS)
Suwon, KR
SD BioSensor Inc., a global leader in in-vitro diagnostics, delivers advanced point-of-care testing solutions from its base in South Korea. The company's diverse product portfolio features the STANDARD Q rapid diagnostic platform, offering quick results for various parameters including COVID-19. For laboratory settings, they provide the STANDARD F, a multi-parametric, random-access fluorescence immunoassay system, and the STANDARD E, an ELISA-based solution ideal for extensive screening programs. Their STANDARD M system brings molecular diagnostics closer to the patient, comprising analyzers, assay menus, qPCR reagents, and nucleic acid extraction kits. Furthermore, the procell Dx range focuses on diagnosing infectious diseases such as tuberculosis and SARS-CoV-2, alongside assessing immune status through interferon-gamma release assays. Blood glucose meters also form part of their offerings. Founded in 2010, SD BioSensor is headquartered in Suwon.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.64% | -8.25% | -7.60% | -7.82% | -17.85% | -14.32% | -33.28% | -53.19% | -87.25% | -87.25% | -87.25% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-08 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+2.3% Q1'26: +4.4% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%-432.3% Q1'26: +221.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+34.8% Q1'26: -8.2% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-11.7% Q1'26: -7.0% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%-3.7% Q1'26: -2.4% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%-0.4% ★ Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×13.22× ★ Q1'26: 4.87× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.93T
est: 3.07T (-4.6%)
|
2.93T
est: 2.95T (-0.8%)
|
655.68B
est: 699.90B (-6.3%)
|
694.57B
est: 717.20B (-3.2%)
|
710.58B
est: 751.40B (-5.4%)
|
824.10B
824.10B – 824.10B
+9.7% YoY
|
908.90B
908.90B – 908.90B
+10.3% YoY
|
1.01T
1.01T – 1.01T
+10.9% YoY
|
1.12T
1.12T – 1.12T
+11.3% YoY
|
| EBITDA |
1.41T
est: 588.65B (+139.0%)
|
1.28T
est: 566.21B (+126.8%)
|
-250.86B
est: 134.11B (-287.1%)
|
-5.37B
est: 86.08B (-106.2%)
|
51.41B
est: 90.18B (-43.0%)
|
98.91B
98.91B – 98.91B
+9.7% YoY
|
109.08B
109.08B – 109.08B
+10.3% YoY
|
120.98B
120.98B – 120.98B
+10.9% YoY
|
134.66B
134.66B – 134.66B
+11.3% YoY
|
| EBIT |
1.46T
est: 318.96B (+359.3%)
|
1.24T
est: 306.80B (+305.2%)
|
-389.39B
est: 72.67B (-635.8%)
|
-147.06B
est: -3.31B (-4,339.8%)
|
-82.86B
est: -3.47B (-2,287.7%)
|
-3.81B
-3.81B – -3.81B
-9.7% YoY
|
-4.20B
-4.20B – -4.20B
-10.3% YoY
|
-4.66B
-4.66B – -4.66B
-10.9% YoY
|
-5.18B
-5.18B – -5.18B
-11.3% YoY
|
| Net Income |
1.09T
est: 2.66T (-59.1%)
|
911.36B
est: 1.37T (-33.5%)
|
-467.71B
est: -389.46B (-20.1%)
|
-98.41B
est: -77.55B (-26.9%)
|
-521.41B
est: -78.28B (-566.1%)
|
-32.14B
-32.14B – -32.14B
+58.9% YoY
|
-18.02B
-18.02B – -18.02B
+43.9% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| SGA |
128.69B
est: 254.08B (-49.4%)
|
88.30B
est: 244.39B (-63.9%)
|
111.08B
est: 57.89B (+91.9%)
|
84.40B
est: 73.69B (+14.5%)
|
105.73B
est: 77.21B (+36.9%)
|
84.68B
84.68B – 84.68B
+9.7% YoY
|
93.39B
93.39B – 93.39B
+10.3% YoY
|
103.57B
103.57B – 103.57B
+10.9% YoY
|
115.29B
115.29B – 115.29B
+11.3% YoY
|
| EPS |
11,161.00
est: 21,778.00 (-48.8%)
|
8,996.76
est: 11,221.50 (-19.8%)
|
-4,218.95
est: -3,187.00 (-32.4%)
|
-804.63
est: -637.00 (-26.3%)
|
-4,282.70
est: -643.00 (-566.0%)
|
-264.00
-264.00 – -264.00
+58.9% YoY
|
-148.00
-148.00 – -148.00
+43.9% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-28 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-27 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-26 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-21 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-20 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-19 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-18 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-15 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chul-Gyu Oh | Chief Financial Officer & Director | — | — |
| Hyo Keun Lee | Vice Chairman & Chief Executive Officer | — | — |
| Tae Young Heo | President & Chief Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 137310.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
